|
|
Eli Lilly And Company (NYSE: LLY) |
|
Price: $1,156.7300
$-17.88 
-1.522%
|
| Day's High:
| $1171.4478759765625
| Week Perf:
| -6.24 %
|
| Day's Low: |
$ 1,147.00 |
30 Day Perf: |
0.69 % |
| Volume (M): |
2,804,948 |
52 Wk High: |
$ 1,292.65 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$1,009.38 |
| Open: |
$1,168.47 |
52 Wk Low: |
$712.05 |
|
|
| Market Capitalization (Millions $) |
1,036,314 |
| Shares
Outstanding (Millions) |
896 |
| Employees |
50,000 |
| Revenues (TTM) (Millions $) |
72,250 |
| Net Income (TTM) (Millions $) |
25,277 |
| Cash Flow (TTM) (Millions $) |
2,189 |
| Capital Exp. (TTM) (Millions $) |
8,658 |
Business Description
Company Profile: Eli Lilly and Company
Overview
Eli Lilly and Company is a global pharmaceutical firm committed to the discovery, development, manufacturing, and sale of pharmaceutical products. The company operates in a single significant business segment—pharmaceuticals—while its animal health division, although operational, does not materially impact its financial statements. Eli Lilly manufactures and distributes its products through various owned and leased facilities located in the United States, Puerto Rico, and 17 other countries, with sales across approximately 140 countries worldwide.
Research and Development
Eli Lillys success is largely driven by its ability to innovate and discover new pharmaceutical products, with a primary focus on preventing and treating human diseases. The company invests substantial resources in research aimed at developing therapeutics across various therapeutic areas, including oncology, neuroscience, diabetes care, and endocrinology. Eli Lilly also conducts research to develop animal health products, enhancing the efficiency of animal food production.
Distribution and Marketing
In the United States, Eli Lilly distributes its pharmaceutical products primarily through independent wholesale distributors, including major players such as AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Corporation. The direct sales to the U.S. government and other manufacturers constitute a minor portion of total sales.
The companys marketing approach ensures that medical information and products are readily available to healthcare professionals, including physicians, pharmacies, and hospitals. A dedicated sales force employs various promotional strategies, including sales representative visits, advertisements in medical journals, the distribution of product samples, and participation in medical conferences.
Eli Lilly also engages in direct-to-consumer advertising for certain products, supported by comprehensive online resources that provide information about its major offerings.
Key Customer Segments
Large purchasers such as managed-care organizations, governmental bodies, and long-term care institutions represent a significant segment of Eli Lillys customer base in the U.S. The company has developed specialized sales teams to address the unique needs of these groups, often providing discounts or rebate arrangements to improve market access.
International Operations
Globally, Eli Lillys promotional activities predominantly rely on sales representatives, with variations in distribution patterns based on regional market dynamics. While neuroscience products form the largest category of total international sales, the company adapts its strategies to accommodate the specific requirements of each market.
Raw Materials and Supply Chain
The raw materials required for manufacturing Eli Lilly products are generally sourced from multiple suppliers, with certain key materials obtained from single sources. The company collaborates with third-party manufacturers for the production of specific pharmaceuticals, and any disruption in material supply could temporarily affect product availability until alternative sources or processes could be established.
Competition
Eli Lilly operates in a highly competitive pharmaceutical landscape, facing rivalry from both established companies and generic manufacturers. Important competitive factors include drug efficacy, safety, pricing, service, and effective marketing and research. As product exclusivity ends, Eli Lillys branded pharmaceuticals confront intensified price competition from generic alternatives. Moreover, in certain international markets where patent protections are weak or non-existent, competition from generic versions of its products becomes even more pronounced.
Conclusion
Eli Lilly and Company remains at the forefront of pharmaceutical innovation, focusing on improving patient outcomes through effective treatments. With a broad global reach and a strong commitment to research and development, Eli Lilly continues to strive to meet the evolving needs of healthcare professionals and patients worldwide.
Company Address: Lilly Corporate Center Zagreb 46285 City of Zagreb
Company Phone Number: 276-2000 Stock Exchange / Ticker: NYSE LLY
|
|
|
Customers Net Income grew by |
LLY's Customers Net Profit Margin grew to |
17.53 % |
4.22 %
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Merger and Acquisition
Published Tue, Mar 25 2025 3:25 PM UTC
Breaking News: Organovo Holdings Completes Strategic Sale of FXR Program to Eli LillySAN DIEGO, March 25, 2025 — Organovo Holdings, Inc. (Nasdaq: ONVO), a pioneering biotechnology firm dedicated to innovative treatments for inflammatory bowel disease (IBD), announced today the successful completion of a significant asset sale of its FXR program, which includes the promisin...
|
| Contract
Published Tue, Mar 25 2025 5:33 PM UTC
Organovo Completes Strategic Sale of FXR Program to Eli Lilly Amid Impressive Financial Growth In a notable strategic transaction in the biotechnology sector, San Diego-based Organovo Holdings, Inc. (Nasdaq: ONVO) has finalized the sale of its FXR program, which includes the leading product FXR314, to pharmaceutical giant Eli Lilly and Company (NYSE: LLY). This move, complet...
|
| Business Update
Published Mon, Jul 8 2024 12:47 PM UTC
GordonMD Global Investments, the prominent investment firm, has announced that its portfolio company, Radionetics Oncology, has entered into a strategic agreement with Eli Lilly and Company, a global pharmaceutical giant. Radionetics Oncology is well-known for its groundbreaking work in developing targeted radiopharmaceuticals for cancer treatment. This collaboration is set ...
|
| Stocks on the Move
Published Mon, Jul 1 2024 4:20 PM UTC
In the competitive world of pharmaceuticals, finding a company that showcases impressive growth potential while maintaining financial stability is a key for investors. Eli Lilly and Company (NYSE:LLY) has recently emerged as an attractive stock option, catching the attention of billionaire investor Ray Dalio. This article delves into the performance and prospects of Eli Lil...
|
| Stocks on the Move
Published Fri, Jun 28 2024 2:24 PM UTC
In recent years, Eli Lilly and Co. (NYSE: LLY) has been at the forefront of innovation, with several noteworthy developments and collaborations in the pharmaceutical industry. However, while the company s stocks have shown promise, its suppliers revenues have declined. This article aims to provide a balanced analysis of recent events surrounding Eli Lilly and Co., shedding ...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
28.14 $ |
| Revenues (TTM) |
80.64 $
|
| Cash Flow (TTM) |
2.44 $ |
| Cash |
5.9 $
|
| Book Value |
34.82 $
|
| Dividend (TTM) |
9.46 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
1,444,990 |
| Net
Income per Employee (TTM) |
505,534 |
| Receivable Turnover Ratio (TTM) |
4.35 |
| Inventory Turnover Ratio (TTM) |
0.96 |
| Asset Turnover Ratio (TTM) |
0.64 |
|
|
| Per Share |
|
| Earnings (TTM) |
28.14 $
|
| Revenues (TTM) |
80.64 $ |
| Cash Flow (TTM) |
2.44 $ |
| Cash |
5.9 $
|
| Book Value |
34.82 $ |
| Dividend (TTM) |
9.46 $ |
|
|
| |
| Net product revenue |
|
 93.2 % |
of total Revenue |
| Collaboration and other revenue |
|
6.8 % |
of total Revenue |
| U S Sales returns rebates and discounts |
|
0 % |
of total Revenue |
| U S |
|
61.21 % |
of total Revenue |
| Outside U S |
|
38.79 % |
of total Revenue |
| Cardiometabolic Health |
|
79.6 % |
of total Revenue |
| Cardiometabolic Health U S |
|
50.12 % |
of total Revenue |
| Cardiometabolic Health Outside U S |
|
29.48 % |
of total Revenue |
| Mounjaro |
|
43.75 % |
of total Revenue |
| Mounjaro U S |
|
21.37 % |
of total Revenue |
| Mounjaro Outside U S |
|
22.37 % |
of total Revenue |
| Zepbound |
|
21.01 % |
of total Revenue |
| Zepbound U S |
|
20.88 % |
of total Revenue |
| Zepbound Outside U S |
|
0.13 % |
of total Revenue |
| Jardiance |
|
5.63 % |
of total Revenue |
| Jardiance U S |
|
2.59 % |
of total Revenue |
| Jardiance Outside U S |
|
3.04 % |
of total Revenue |
| Trulicity |
|
4.64 % |
of total Revenue |
| Trulicity U S |
|
3.03 % |
of total Revenue |
| Trulicity Outside U S |
|
1.61 % |
of total Revenue |
| Other cardiometabolic health |
|
4.57 % |
of total Revenue |
| Other cardiometabolic health U S |
|
2.25 % |
of total Revenue |
| Other cardiometabolic health Outside U S |
|
2.32 % |
of total Revenue |
| Oncology |
|
11.46 % |
of total Revenue |
| Oncology U S |
|
6.2 % |
of total Revenue |
| Oncology Outside U S |
|
5.25 % |
of total Revenue |
| Verzenio |
|
6.58 % |
of total Revenue |
| Verzenio U S |
|
3.57 % |
of total Revenue |
| Verzenio Outside U S |
|
3.01 % |
of total Revenue |
| Other oncology |
|
4.88 % |
of total Revenue |
| Other oncology U S |
|
2.64 % |
of total Revenue |
| Other oncology Outside U S |
|
2.24 % |
of total Revenue |
| Immunology |
|
6.08 % |
of total Revenue |
| Immunology U S |
|
3.13 % |
of total Revenue |
| Immunology Outside U S |
|
2.95 % |
of total Revenue |
| Taltz |
|
3.7 % |
of total Revenue |
| Taltz U S |
|
2.11 % |
of total Revenue |
| Taltz Outside U S |
|
1.59 % |
of total Revenue |
| Other immunology |
|
2.37 % |
of total Revenue |
| Other immunology U S |
|
1.02 % |
of total Revenue |
| Other immunology Outside U S |
|
1.36 % |
of total Revenue |
| Neuroscience |
|
1.93 % |
of total Revenue |
| Neuroscience U S |
|
1.48 % |
of total Revenue |
| Neuroscience Outside U S |
|
0.45 % |
of total Revenue |
| Other |
|
0.94 % |
of total Revenue |
| Other U S |
|
0.28 % |
of total Revenue |
| Other Outside U S |
|
0.66 % |
of total Revenue |
| Europe |
|
18.42 % |
of total Revenue |
| China |
|
3.5 % |
of total Revenue |
| Japan |
|
2.88 % |
of total Revenue |
| Rest of world |
|
14 % |
of total Revenue |
| Reportable Segment |
|
100 % |
of total Revenue |
|
|
1.75%